Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib
2019年7月2日 更新者:AHS Cancer Control Alberta
Evaluation of Technetium-99m Sestamibi to Determine Muscle Energy Metabolism in RCC (Renal Cell Cancer) Patients Treated With Sunitinib
Sunitinib is a chemotherapy approved by the FDA as a standard of care treatment for renal cell carcinoma (RCC).
Fatigue is a very common side effect of sunitinib that frequently causes dose reductions.
The cause of this fatigue remains unclear.
This study will use a special type of scan to study sunitinib-induced fatigue in relation to exercise.
研究概览
地位
地位
撤销
详细说明
Sunitinib, a type of tyrosine kinase inhibitor (TKI) has been approved by the FDA as a standard of care treatment for renal cell carcinoma (RCC).
Fatigue is a very common side effect of sunitinib that frequently causes dose reductions.
The cause of this fatigue remains unclear.
It has been shown that TKIs disrupt growth factor pathways in muscles leading to muscle shrinkage.
If sunitinib associated fatigue is due to altered muscle physiology at a molecular level, there will be observable changes in the uptake of 99mTc-sestamibi in scintigraphy scans.
The study objective is to determine if sunitinib-induced fatigue as determined by VO2 and QOL fatigue related questionnaire responses are correlated to molecular changes in the muscles as evidenced by 99mTc-sestamibi uptake.
研究类型
研究类型
观察性的
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Alberta
-
Edmonton、Alberta、加拿大、T6G 1Z2
- Cross Cancer Institute
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
取样方法
非概率样本
研究人群
Men and women aged 18 years of age or older with a confirmed diagnosis of renal cell carcinoma.
Participants will receive standard of care treatment with sunitinib.
Participants must be willing to undergo exercise testing and diagnostic imaging with technitium 99m-sestamibi
描述
Inclusion Criteria:
- Signed informed consent before any study procedures completed
- Patients must have histologically or cytologically confirmed RCC.
- Four weeks must have elapsed since prior chemotherapy, hormonal therapy, targeted therapy or radiation therapy. There is no restriction on the amount of bone marrow previously radiated.
- Recovery to baseline or, at most, grade 1 of all drug-related toxicities due to prior chemotherapy, radiation, hormonal therapy, or molecular targeted therapy, expect for alopecia.
- Male / female subject ≥ 18 years of age
- Eastern Cooperative Oncology Group (ECOG) Performance Status of <2 (Karnofsky >70%)
- Life expectancy of at least 12 weeks
Normal organ and marrow function as defined by :
- absolute neutrophil count (ANC) > 1500/mcL
- hemoglobin (Hb) > 90 g/L
- platelet count ≥ 1000.000/mcL,
- total bilirubin ≤ 1.5 x the upper limit of normal range (ULN)
- alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN (<5 x ULN presence of liver metastases)
- creatinine < 1.5 x institutional ULN
- Cardiac ejection fraction by MUGA scan or echocardiogram must be >50% for patients at baseline.
- Ability to understand the purpose of the study and the willingness to sign a written informed consent document
- Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment. Standard Nuclear Medicine department pregnancy screening will be conducted prior to each 99mTc-sestamibi scan. Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. The investigator is requested to advise the patient how to achieve an adequate contraception.
- Patients must give written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.
Exclusion Criteria:
- Patients who have had chemotherapy, hormonal therapy, molecular targeted therapy, or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- Patients may not be receiving any other investigational agents, chemotherapy, immunotherapy, radiotherapy, or molecular targeted agents.
- Prior treatment with a drug with known anti-angiogenic properties, including other tyrosine kinase inhibitors to VEGFR
- Any psychological, familial, sociological, or geographical conditions that do not permit medical follow-up and compliance with the study protocol.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, HIV, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients that are on therapeutic dose of coumadin or an INR of 1.5 c ULN. Patients that are on low dose coumadin (2mg or less for patency of the central venous catheter) or therapeutic dose of low molecular weight heparin will be allowed.
- Patients who cannot swallow
- Patients who are breast-feeding.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
99mTc-sestamibi uptake in muscle cells
大体时间:12 weeks from start of treatment
|
12 weeks from start of treatment
|
|
99mTc-sestamibi uptake in muscle cells
大体时间:24 weeks from start of treatment
|
24 weeks from start of treatment
|
|
99mTc-sestamibi uptake in muscle cells
大体时间:36 weeks from start of treatment
|
36 weeks from start of treatment
|
次要结果测量
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Incidence of sunitinib related fatigue
大体时间:36 weeks after the start of sunitinib treatment
|
36 weeks after the start of sunitinib treatment
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
调查人员
- 首席研究员:Michael Sawyer, MD、Alberta Health services
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
学习开始
2015年6月1日
初级完成 (实际的)
初级完成
2019年3月18日
研究完成 (实际的)
研究完成
2019年3月18日
研究注册日期
首次提交
首次提交
2015年4月21日
首先提交符合 QC 标准的
首先提交符合 QC 标准的
2015年4月23日
首次发布 (估计)
首次发布
2015年4月28日
研究记录更新
最后更新发布 (实际的)
最后更新发布
2019年7月5日
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
2019年7月2日
最后验证
最后验证
2019年7月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.